Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nerviano Medical Sciences SRL

www.nervianoms.com

Latest From Nerviano Medical Sciences SRL

Roche Ramps Up Cancer Portfolio With $1.7bn Ignyta Buy

The Swiss giant's acquisition of Ignyta to get hold of the latter's closely-watched NSCLC drug entrectinib will potentially trigger an intriguing fight for market share in the near future with Loxo Oncology and Bayer's larotrectinib.

M & A Cancer

China Investment Roundup: Active Deal-Making In Precision Medicine

Winter is coming, yet China’s financial market is still hot for healthcare companies looking at a prosperous period of investment before the year ends. Capital investments from Chinese investors dramatically increased in November, particularly in the precision medicines segment. Although Chinese Creat Group’s expected record-breaking outbound pharmaceutical acquisition deal worth $1.5bn failed to gain US approval, cross-border M&A remained active.

China Commercial

UK Charity Starts Early-Stage Clinical Studies Of Lilly's Cdc7 Inhibitor

The drug development arm of the UK charity, Cancer Research UK, has started early clinical development of potentially a new type of anticancer, a Cdc7 inhibitor, discovered by Eli Lilly, in an effort that could boost traction in this new area of research.

Clinical Trials Cancer

Ibrance Trial Cements CDK4/6 Inhibitors As Standard Of Care In Breast Cancer

New England Journal of Medicine editorial sings the praises of CDK4/6 inhibitors in breast cancer, which include Pfizer's Ibrance, Novartis's ribociclib and Elli Lilly's abemaciclib.

Cancer Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Italy
  • Parent & Subsidiaries
  • Nerviano Medical Sciences SRL
  • Senior Management
  • Andrea Agazzi, Pres.
  • Contact Info
  • Nerviano Medical Sciences SRL
    Phone: (39) 331 581 111
    Srl - Viale L. Pasteur, 10
    Milan, 20014
    Italy
Advertisement
Advertisement
UsernamePublicRestriction

Register